Orion Oyj (OTCMKTS:ORINY) Releases Quarterly Earnings Results

Orion Oyj (OTCMKTS:ORINY) issued its earnings results on Tuesday. The company reported $0.28 earnings per share for the quarter, Zacks reports. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%.

Orion Oyj Stock Performance

OTCMKTS ORINY opened at $27.03 on Tuesday. The business’s 50-day moving average price is $24.65 and its 200 day moving average price is $25.07. The firm has a market cap of $7.63 billion, a P/E ratio of 21.45 and a beta of 0.25. Orion Oyj has a 52-week low of $17.50 and a 52-week high of $28.55. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25.

Analyst Ratings Changes

Separately, Nordea Equity Research downgraded Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.